| . | Patient 1 (3 mo) . | Patient 1 (8 mo) . | Normal range . | Patient 2 (9 yr) . | Patient (11 yr) . | Normal range . |
|---|---|---|---|---|---|---|
| Peripheral blood | ||||||
| White blood cells (×103/µl) | 85.5 | 7.4 | 6–17.5 | 3.46 | 10.6 | 5.4–9.7 |
| Hemoglobin (g/dl) | 9.5 | 11 | 9.5–13.5 | 6.60 | 12.4 | 11.3–13.4 |
| RBC (x106/µl) | 3.16 | 4.84 | 3.5–5.5 | 3.02 | 5.65 | 4.00–5.20 |
| MCV (fl) | 95.9 | 82 | 80–100 | 66.4 | 62.5 | 77–90 |
| MCH (pg) | 30.1 | 27.5 | 27–31 | 22 | 18.9 | 25–30 |
| Reticulocyte count (%) | 2.4 | 0.5–1.5 | 0.3 | 0.5–1.5 | ||
| Direct Coombs test | Negative | Negative | Negative | Negative | ||
| Platelets (×103/µl) | 234 | 236 | 150–450 | 71 | 188 | 150–450 |
| Neutrophils (×103/µl) | 21.4 | 2.1 | 1–8.5 | 1.66 | 2.84 | 2.5–5.95 |
| Lymphocytes (×103/µl) | 51 | 3.3 | 4.0–10.5 | 1.38 | 5.07 | 1.23–2.76 |
| Monocytes (×103/µl) | 7.7 | 1.8 | 0.2–1.2 | 0.42 | 0.87 | 0.10–1.11 |
| Eosinophils (×103/µl) | 1.5 | <0.81 | 0 | 0.12 | 0.04–0.19 | |
| Lymphocyte subsetsa | ||||||
| CD3 (×103 cells/ml) | 40.8 | 4.67 | 1.85–5.96 | 0.43 | 3.78 | 1–2.6 |
| CD3/CD4 (×103 cells/ml) | 10.2 | 1.28 | 1.14–3.8 | 0.25 | 1.69 | 0.53–1.5 |
| CD3/CD8 (×103 cells/ml) | 30.6 | 3.24 | 0.54–1.97 | 0.16 | 2.38 | 0.33–1.1 |
| CD4/CD8 ratio | 0.3 | 0.39 | 1.6–3.8 | 1.05 | 0.58 | 1.1–1.6 |
| CD3/CD25 (×103 cells/ml) | - | - | 56 | 328 | 100–400 | |
| CD19 (×103 cells/ml) | 5.6 | 0.69 | 0.64–1.96 | 0.57 | 1.55 | 0.27–8.6 |
| CD16/CD56 (×103 cells/ml) | 4.5 | 0.40 | 0.15–1.33 | 0.57 | 0.21 | 0.07–0.48 |
| % in CD4+ T cells | ||||||
| T reg (CD25+CD127−Foxp3+) | - | 5.6 | 6.3–8.5* | - | 7.4 | 7.6–9.9* |
| Naive (CD45RA+CCR7+) | - | 33 | 74–90* | - | 34 | 67–83* |
| CM (CD45RA−CCR7+) | - | 20 | 8–18* | - | 50 | 12–23* |
| EM (CD45RA−CCR7−) | - | 34 | 2–5* | - | 15 | 4–9* |
| TEMRA (CD45RA+CCR7−) | - | 3 | 0–5* | - | 1 | 1–2* |
| CD57+ | - | 6.5 | 1–2* | - | 3.8 | 0–2* |
| CD69+ | - | 21 | 5–9* | - | 5.0 | 5–7* |
| CD95+ | - | 69 | 12–24* | - | 66.9 | 18–36* |
| HLA-DR+ | - | 7 | 2–4* | - | 5.3 | 2–9* |
| PD1+ | - | 36 | 16–26* | - | 34.3 | 17–22* |
| % in CD8+ T cells | ||||||
| Naive (CD45RA+CCR7+) | - | 6 | 60–85* | - | 12 | 56–74* |
| CM (CD45RA−CCR7+) | - | 1 | 0–6* | - | 10 | 2–4* |
| EM (CD45RA−CCR7−) | - | 5 | 2–10* | - | 21 | 6–14* |
| TEMRA (CD45RA+CCR7−) | - | 88 | 6–28* | - | 57 | 13–30* |
| CD57+ | - | 49 | 0–16* | - | 58 | 4–20* |
| CD69+ | - | 22 | 6–21* | - | 17 | 12–24* |
| CD95+ | - | 61 | 0–18* | - | 36 | 14–34* |
| HLA-DR+ | - | 30 | 5–17* | - | 21 | 5–15* |
| PD1+ | - | 35 | 19–25* | - | 25 | 16–31* |
| % in CD19+ B cells | ||||||
| Naive (IgD+CD27−) | - | 90 | 69–86* | - | 93 | 64–86* |
| Switched memory (IgD+CD27−) | - | 1 | 3–10* | - | 3 | 5–17* |
| Unswitched memory (IgD+CD27+) | - | 1 | 7–10* | - | 3 | 5–15* |
| Transitional (CD24+CD38+) | - | 10 | 8–19* | - | 9 | 7–15* |
| CD21− | - | 77 | 4–14* | - | 2 | 2–5* |
| % in monocytes | ||||||
| Classical (CD14+CD16−) | - | 9 | 59–80* | - | 72 | 80–85* |
| Transient (CD14+CD16+) | - | 10 | 6–14* | - | 17 | 3–5* |
| Resident (CD14loCD16+) | - | 75 | 5–12* | - | 2 | 2–6* |
| % in CD3−CD56+ NK cells | ||||||
| CD16−CD56++ | - | 18 | 2–8* | - | 18 | 5–10* |
| NKp30+ | - | 26 | 69–86** | - | 51 | 64–81* |
| NKp44+ | - | 8 | 0–11* | - | 7 | 1–4* |
| NKp46+ | - | 96 | 96–98* | - | 95 | 94–97* |
| NKG2C+ | - | 11 | 0–69** | - | 10 | 7–19** |
| NKG2D+ | - | 98 | 97–98* | - | 93 | 84–100* |
| CD57+ | - | 10 | 0–49* | - | 28 | 10–23** |
| Igs | ||||||
| IgA (mg/dl) | 130 | 169 | 4–69 | 1,820 | 680 | 70–400 |
| IgG (mg/dl) | 2,581 | 1,680 | 196–560 | 15,900 | 22,500 | 700–1,600 |
| IgM (mg/dl) | >1,000 | 9,550 | 25–93 | 1,340 | 1,160 | 40–230 |
| IgE (IU/ml) | 60 | 22.9 | <15 | 358 | 197 | 0–500 |
| Serology | ||||||
| Antinuclear antibodies titer | - | Positive at 1/1,280 dilution | <1/80 | Negative | - | <1/80 |
| Anti-dsDNA (IU/ml) | - | Negative | <50 | Negative | - | <200 |
| Tetanus titer (IU/ml) | Protective | Protective | >0.15 | Protective | Protective | >0.15 |
| Others | ||||||
| Ferritin (ng/ml) | 1,190 | 241 | 36–100 | 14,280 | 76.9 | 21–274 |
| Fibrinogen (mg/liter) | 0.64 | 0.83 | 1.5–3.5 | 1.07 | 3.83 | 1.50–4.10 |
| Triglycerides (mg/dl) | 1,140 | 1,940 | 20–150 | 612 | 174 | 20–150 |
| AST (U/liter) | 141 | 84 | 6–50 | 301 | 102 | 5–34 |
| ALT (U/liter) | 21 | 35 | 20–60 | 313 | 121 | 5–55 |
| Total bilirubin (µmol/liter) | 6.84 | 3.42 | 3.4–17.1 | 15.1 | 5.1 | 3.4–17.1 |
| Conjugated | 3.42 | - | <5.9 | 14.2 | - | <5.9 |
| Unconjugated | 3.42 | - | <17.1 | 0.9 | - | <17.1 |
| Alk Phos (IU/liter) | 709 | 680 | 110–320 | 174 | 221 | 141–460 |
| Haptoglobin (g/liter) | - | - | - | 0.47 | - | <2.7 |
| LDH (IU/liter) | - | 2,835 | 500–920 | 948 | 432–700 | |
| ESR (mm/h) | 1 | 20 | 0–10 | 28 | 25 | 0–15 |
| CRP (mg/liter) | 1 | 1 | <6 | 208 | 5 | < 8 |
| sIL-2R (U/ml) | - | 3,202 | 223–710 | - | 1,701 | 223–710 |
| IFN-γ (pg/ml) | - | 5.3 | 1.7–66.5b | - | 339 | 0.3–11.0c |
| IL-10 (pg/ml) | - | 48.3 | 0–2.5b | - | 12.6 | 0–10.3c |
| IL-18 (pg/ml) | - | 3,698 | 17–145b | - | 2,130 | 266–1,300c |
| IP-10 (pg/ml) | - | 228 | 25–68b | - | 518 | 37–245c |
| IL12p40 (pg/ml) | - | 676 | 0.0–74b | - | 152 | 0.0–65c |
| . | Patient 1 (3 mo) . | Patient 1 (8 mo) . | Normal range . | Patient 2 (9 yr) . | Patient (11 yr) . | Normal range . |
|---|---|---|---|---|---|---|
| Peripheral blood | ||||||
| White blood cells (×103/µl) | 85.5 | 7.4 | 6–17.5 | 3.46 | 10.6 | 5.4–9.7 |
| Hemoglobin (g/dl) | 9.5 | 11 | 9.5–13.5 | 6.60 | 12.4 | 11.3–13.4 |
| RBC (x106/µl) | 3.16 | 4.84 | 3.5–5.5 | 3.02 | 5.65 | 4.00–5.20 |
| MCV (fl) | 95.9 | 82 | 80–100 | 66.4 | 62.5 | 77–90 |
| MCH (pg) | 30.1 | 27.5 | 27–31 | 22 | 18.9 | 25–30 |
| Reticulocyte count (%) | 2.4 | 0.5–1.5 | 0.3 | 0.5–1.5 | ||
| Direct Coombs test | Negative | Negative | Negative | Negative | ||
| Platelets (×103/µl) | 234 | 236 | 150–450 | 71 | 188 | 150–450 |
| Neutrophils (×103/µl) | 21.4 | 2.1 | 1–8.5 | 1.66 | 2.84 | 2.5–5.95 |
| Lymphocytes (×103/µl) | 51 | 3.3 | 4.0–10.5 | 1.38 | 5.07 | 1.23–2.76 |
| Monocytes (×103/µl) | 7.7 | 1.8 | 0.2–1.2 | 0.42 | 0.87 | 0.10–1.11 |
| Eosinophils (×103/µl) | 1.5 | <0.81 | 0 | 0.12 | 0.04–0.19 | |
| Lymphocyte subsetsa | ||||||
| CD3 (×103 cells/ml) | 40.8 | 4.67 | 1.85–5.96 | 0.43 | 3.78 | 1–2.6 |
| CD3/CD4 (×103 cells/ml) | 10.2 | 1.28 | 1.14–3.8 | 0.25 | 1.69 | 0.53–1.5 |
| CD3/CD8 (×103 cells/ml) | 30.6 | 3.24 | 0.54–1.97 | 0.16 | 2.38 | 0.33–1.1 |
| CD4/CD8 ratio | 0.3 | 0.39 | 1.6–3.8 | 1.05 | 0.58 | 1.1–1.6 |
| CD3/CD25 (×103 cells/ml) | - | - | 56 | 328 | 100–400 | |
| CD19 (×103 cells/ml) | 5.6 | 0.69 | 0.64–1.96 | 0.57 | 1.55 | 0.27–8.6 |
| CD16/CD56 (×103 cells/ml) | 4.5 | 0.40 | 0.15–1.33 | 0.57 | 0.21 | 0.07–0.48 |
| % in CD4+ T cells | ||||||
| T reg (CD25+CD127−Foxp3+) | - | 5.6 | 6.3–8.5* | - | 7.4 | 7.6–9.9* |
| Naive (CD45RA+CCR7+) | - | 33 | 74–90* | - | 34 | 67–83* |
| CM (CD45RA−CCR7+) | - | 20 | 8–18* | - | 50 | 12–23* |
| EM (CD45RA−CCR7−) | - | 34 | 2–5* | - | 15 | 4–9* |
| TEMRA (CD45RA+CCR7−) | - | 3 | 0–5* | - | 1 | 1–2* |
| CD57+ | - | 6.5 | 1–2* | - | 3.8 | 0–2* |
| CD69+ | - | 21 | 5–9* | - | 5.0 | 5–7* |
| CD95+ | - | 69 | 12–24* | - | 66.9 | 18–36* |
| HLA-DR+ | - | 7 | 2–4* | - | 5.3 | 2–9* |
| PD1+ | - | 36 | 16–26* | - | 34.3 | 17–22* |
| % in CD8+ T cells | ||||||
| Naive (CD45RA+CCR7+) | - | 6 | 60–85* | - | 12 | 56–74* |
| CM (CD45RA−CCR7+) | - | 1 | 0–6* | - | 10 | 2–4* |
| EM (CD45RA−CCR7−) | - | 5 | 2–10* | - | 21 | 6–14* |
| TEMRA (CD45RA+CCR7−) | - | 88 | 6–28* | - | 57 | 13–30* |
| CD57+ | - | 49 | 0–16* | - | 58 | 4–20* |
| CD69+ | - | 22 | 6–21* | - | 17 | 12–24* |
| CD95+ | - | 61 | 0–18* | - | 36 | 14–34* |
| HLA-DR+ | - | 30 | 5–17* | - | 21 | 5–15* |
| PD1+ | - | 35 | 19–25* | - | 25 | 16–31* |
| % in CD19+ B cells | ||||||
| Naive (IgD+CD27−) | - | 90 | 69–86* | - | 93 | 64–86* |
| Switched memory (IgD+CD27−) | - | 1 | 3–10* | - | 3 | 5–17* |
| Unswitched memory (IgD+CD27+) | - | 1 | 7–10* | - | 3 | 5–15* |
| Transitional (CD24+CD38+) | - | 10 | 8–19* | - | 9 | 7–15* |
| CD21− | - | 77 | 4–14* | - | 2 | 2–5* |
| % in monocytes | ||||||
| Classical (CD14+CD16−) | - | 9 | 59–80* | - | 72 | 80–85* |
| Transient (CD14+CD16+) | - | 10 | 6–14* | - | 17 | 3–5* |
| Resident (CD14loCD16+) | - | 75 | 5–12* | - | 2 | 2–6* |
| % in CD3−CD56+ NK cells | ||||||
| CD16−CD56++ | - | 18 | 2–8* | - | 18 | 5–10* |
| NKp30+ | - | 26 | 69–86** | - | 51 | 64–81* |
| NKp44+ | - | 8 | 0–11* | - | 7 | 1–4* |
| NKp46+ | - | 96 | 96–98* | - | 95 | 94–97* |
| NKG2C+ | - | 11 | 0–69** | - | 10 | 7–19** |
| NKG2D+ | - | 98 | 97–98* | - | 93 | 84–100* |
| CD57+ | - | 10 | 0–49* | - | 28 | 10–23** |
| Igs | ||||||
| IgA (mg/dl) | 130 | 169 | 4–69 | 1,820 | 680 | 70–400 |
| IgG (mg/dl) | 2,581 | 1,680 | 196–560 | 15,900 | 22,500 | 700–1,600 |
| IgM (mg/dl) | >1,000 | 9,550 | 25–93 | 1,340 | 1,160 | 40–230 |
| IgE (IU/ml) | 60 | 22.9 | <15 | 358 | 197 | 0–500 |
| Serology | ||||||
| Antinuclear antibodies titer | - | Positive at 1/1,280 dilution | <1/80 | Negative | - | <1/80 |
| Anti-dsDNA (IU/ml) | - | Negative | <50 | Negative | - | <200 |
| Tetanus titer (IU/ml) | Protective | Protective | >0.15 | Protective | Protective | >0.15 |
| Others | ||||||
| Ferritin (ng/ml) | 1,190 | 241 | 36–100 | 14,280 | 76.9 | 21–274 |
| Fibrinogen (mg/liter) | 0.64 | 0.83 | 1.5–3.5 | 1.07 | 3.83 | 1.50–4.10 |
| Triglycerides (mg/dl) | 1,140 | 1,940 | 20–150 | 612 | 174 | 20–150 |
| AST (U/liter) | 141 | 84 | 6–50 | 301 | 102 | 5–34 |
| ALT (U/liter) | 21 | 35 | 20–60 | 313 | 121 | 5–55 |
| Total bilirubin (µmol/liter) | 6.84 | 3.42 | 3.4–17.1 | 15.1 | 5.1 | 3.4–17.1 |
| Conjugated | 3.42 | - | <5.9 | 14.2 | - | <5.9 |
| Unconjugated | 3.42 | - | <17.1 | 0.9 | - | <17.1 |
| Alk Phos (IU/liter) | 709 | 680 | 110–320 | 174 | 221 | 141–460 |
| Haptoglobin (g/liter) | - | - | - | 0.47 | - | <2.7 |
| LDH (IU/liter) | - | 2,835 | 500–920 | 948 | 432–700 | |
| ESR (mm/h) | 1 | 20 | 0–10 | 28 | 25 | 0–15 |
| CRP (mg/liter) | 1 | 1 | <6 | 208 | 5 | < 8 |
| sIL-2R (U/ml) | - | 3,202 | 223–710 | - | 1,701 | 223–710 |
| IFN-γ (pg/ml) | - | 5.3 | 1.7–66.5b | - | 339 | 0.3–11.0c |
| IL-10 (pg/ml) | - | 48.3 | 0–2.5b | - | 12.6 | 0–10.3c |
| IL-18 (pg/ml) | - | 3,698 | 17–145b | - | 2,130 | 266–1,300c |
| IP-10 (pg/ml) | - | 228 | 25–68b | - | 518 | 37–245c |
| IL12p40 (pg/ml) | - | 676 | 0.0–74b | - | 152 | 0.0–65c |
“-” indicates test not done. Normal-range values are either those of the local diagnostic laboratory and/or reported from Gregory and Andropoulos (2012). * and ** correspond to 5th and 95th percentile of values obtained from eight age-matched controls and, in some rare cases, from three age-matched controls, respectively. Alk Phos., alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; dsDNA, double-stranded DNA; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; T reg cells, regulatory T cells.
Normal range for absolute numbers of lymphocyte subsets were from age-matched routine clinical lab values.
Normal range shows 5th and 95th percentile of serum cytokine levels calculated among 22 healthy subjects.
Normal range shows 5th and 95th percentile of plasma cytokine levels calculated among 10 healthy subjects.